SCHEMBL25440079

SCHEMBL25440079

CSc1nnc(-c2ccc(NC(=O)O)cc2)nn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ KMT2A Q03164 8/20 0.41
▸ ALDH1A1 P00352 6/20 0.41
▸ MEN1 O00255 5/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ HPGD P15428 4/20 0.41
▸ RXFP1 Q9HBX9 2/20 0.41
▸ RAB9A P51151 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ RGS12 O14924 1/20 0.38
▸ AHR P35869 1/20 0.38
▸ PRNP P04156 1/20 0.38
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26330221 0.80 CYP17A1 (0.52) —
SCHEMBL25439850 0.76 MAPT (0.43) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL25440037 0.75 TSHR (0.48) MAPTHSD17B10KMT2AALDH1A1MEN1
SCHEMBL23405207 0.73 RAB9A (0.64) MAPTKMT2AALDH1A1KDM4EHPGD
SCHEMBL28386018 0.72 SMN1; SMN2 (0.61) MAPTALDH1A1KDM4ERAB9ANPC1
SCHEMBL836968 0.71 ALDH1A1 (0.62) MAPTHSD17B10KMT2AALDH1A1MEN1
SCHEMBL25440108 0.70 LMNA (0.43) MAPTHSD17B10KMT2AALDH1A1MEN1
SCHEMBL10778839 0.70 SMN1; SMN2 (0.52) MAPTHSD17B10KMT2ARAB9ANPC1
SCHEMBL10049752 0.69 NPC1 (0.71) MAPTALDH1A1KDM4ERXFP1RAB9A
SCHEMBL22340625 0.68 USP2 (0.32) MAPTHSD17B10KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767302-B2 Reagents and methods for tetrazine synthesis UNIVERSITY OF DELAWARE (US) 2023-09-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11767302-B2 Reagents and methods for tetrazine synthesis TST, CYP4F8, CYP4Z1 MAPT 1269/4885HSD17B10 616/4885KMT2A 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback